Latest WHO-Approved Cholera Vaccine Shows Promise Of Partnerships In Innovation, Funding

Devex: Stocking up to defeat cholera
Anita Zaidi, director of the enteric and diarrheal diseases (EDD) program at the Bill & Melinda Gates Foundation

“…The latest [WHO-approved cholera vaccine], called Euvichol, produced by Eubiologics in South Korea, was developed in partnership with the International Vaccine Institute, also based in South Korea. It is the first vaccine produced in the country for global health purposes, a noteworthy contribution that demonstrates the unique power of diverse partnerships to successfully develop, manufacture, and distribute vaccines. The Euvichol financing represents an innovative collaboration among an international consortium of public, private, and nonprofit organizations. Structured by JPMorgan Chase & Co. and the Bill & Melinda Gates Foundation, the Global Health Investment Fund is a private investment fund designed to finance late-stage technologies for diseases that disproportionately burden low-income populations. … It’s clear that vaccinations, along with improved hygiene and sanitation, will be vital to prevent future outbreaks. … [I]t will be essential for all partners involved to remain committed and follow through on their promises to protect vulnerable populations from cholera and ensure that communities can thrive without fear of a cholera outbreak” (1/12).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.